445 followers
RT @FrontEndocrinol: New Research: Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequate…
RT @FrontEndocrinol: New Research: Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequate…
New Research: Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs: Introduction: Acromegaly is a rare, serious endocrine… https://t.co/q1yfNdCu0j #